AbbVie Faces 1st Antitrust Suit Over Humira 'Patent Thicket'
AbbVie Inc.'s colossal "patent thicket" for its $20-billion-per-year immunosuppressant Humira has empowered it to block less-expensive biosimilars in violation of numerous antitrust laws, according to a first-of-its-kind suit launched Monday....To view the full article, register now.
Already a subscriber? Click here to view full article